Photomicrograph of colonic crypts showing foci of apoptotic nuclear debris, a feature of graft-versus-host disease. Credit: Mark ong/commons.wikimedia.org.
Australia Health and Aged Care minister Hon Mark Butler said: “The listings of these medicines on the PBS will be life changing for patients across Australia.
“Time is of the essence for patients living with GVHD and their caregivers, who have had no other, or limited, treatment options until now.
“Instead of spending tens of thousands of dollars on treatments the Government has listed these medicines on the PBS so patients will only pay a maximum of A$30 ($20) per course of treatment.”
Jakavi is indicated to treat either acute, or moderate to severe chronic GVHD patients who do not respond to, are dependent on, or intolerant to corticosteroids.
The new treatment option is expected to benefit 225 patients with acute or chronic GVHD, which is a serious complication of stem cell transplants, each year.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.